State of Alaska Department of Revenue Boosts Position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
State of Alaska Department of Revenue boosted its position in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 78.9% during the second quarter, Holdings Channel reports. The fund owned 1,592 shares of the specialty pharmaceutical company’s stock after buying an additional 702 shares during the period. State of Alaska Department of Revenue’s holdings in Eagle Pharmaceuticals were worth $125,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in EGRX. Fisher Asset Management LLC increased its position in Eagle Pharmaceuticals by 43.8% in the second quarter. Fisher Asset Management LLC now owns 11,045 shares of the specialty pharmaceutical company’s stock valued at $871,000 after buying an additional 3,365 shares in the last quarter. Bank of Montreal Can increased its position in Eagle Pharmaceuticals by 323.9% in the second quarter. Bank of Montreal Can now owns 2,497 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 1,908 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its position in Eagle Pharmaceuticals by 48.0% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 3,700 shares of the specialty pharmaceutical company’s stock valued at $307,000 after buying an additional 1,200 shares in the last quarter. First Financial Equity Corporation bought a new position in Eagle Pharmaceuticals during the first quarter valued at approximately $570,000. Finally, Jane Street Group LLC bought a new position in Eagle Pharmaceuticals during the first quarter valued at approximately $220,000.
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) traded up 9.91% on Friday, hitting $55.03. The stock had a trading volume of 250,436 shares. The firm has a market cap of $834.75 million, a price-to-earnings ratio of 9.24 and a beta of 1.31. The company’s 50 day moving average price is $68.13 and its 200 day moving average price is $76.11. Eagle Pharmaceuticals, Inc. has a 52-week low of $45.05 and a 52-week high of $97.15.
Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.33 EPS for the quarter, missing the Zacks’ consensus estimate of $0.51 by $0.18. Eagle Pharmaceuticals had a net margin of 39.32% and a return on equity of 66.30%. The business had revenue of $50.10 million during the quarter, compared to the consensus estimate of $52.52 million. During the same period in the previous year, the business posted $0.80 EPS. The firm’s revenue was up 22.5% on a year-over-year basis. Analysts expect that Eagle Pharmaceuticals, Inc. will post $3.38 EPS for the current year.
Eagle Pharmaceuticals declared that its Board of Directors has approved a share buyback plan on Wednesday, August 9th that allows the company to repurchase $100.00 million in shares. This repurchase authorization allows the specialty pharmaceutical company to buy up to 13.3% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its shares are undervalued.
WARNING: This news story was first reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/state-of-alaska-department-of-revenue-boosts-position-in-eagle-pharmaceuticals-inc-nasdaqegrx/1475833.html.
Several research firms have recently commented on EGRX. Zacks Investment Research downgraded Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Royal Bank Of Canada set a $86.00 price objective on Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, April 24th. Piper Jaffray Companies set a $118.00 price objective on Eagle Pharmaceuticals and gave the stock an “overweight” rating in a report on Tuesday, May 9th. ValuEngine upgraded Eagle Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 16th. Finally, BidaskClub downgraded Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 30th. Three investment analysts have rated the stock with a sell rating and four have given a buy rating to the company. Eagle Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $75.40.
In other Eagle Pharmaceuticals news, CFO Pete A. Meyers purchased 350 shares of the stock in a transaction that occurred on Monday, June 12th. The stock was purchased at an average price of $71.49 per share, with a total value of $25,021.50. Following the acquisition, the chief financial officer now owns 350 shares in the company, valued at $25,021.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders purchased 805 shares of company stock valued at $61,790. 19.50% of the stock is owned by insiders.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.
Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX).
Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.